OncoMatch/Clinical Trials/NCT06541847
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
Is NCT06541847 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies HLX-1502 for neurofibromatosis type 1.
Treatment: HLX-1502 — The trial will be an open label, single arm, phase 2 study to assess the tolerability and efficacy of HLX-1502 in participants with NF1 that are 16 years or older in age with progressive and/or symptomatic PN. This study will also investigate the safety and efficacy of HLX-1502 in a small cohort of 12 to 15 year olds.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Demographics
Prior therapy
Cannot have received: HLX-1502 (HLX-1502)
Prior treatment with HLX-1502 for a PN
Cannot have received: MEK inhibitor
MEK-inhibitors
Cannot have received: tyrosine kinase inhibitor
other drugs in the TKI class
Cannot have received: myelosuppressive chemotherapy
Myelosuppressive chemotherapy
Cannot have received: hematopoietic growth factors
Hematopoietic growth factors
Cannot have received: biologic (anti-neoplastic agent)
Biologic (anti-neoplastic agent)
Cannot have received: investigational drug
Investigational Drugs
Cannot have received: systemically administered anti-neoplastic agent
Any other systemically administered anti-neoplastic agent
Cannot have received: radiation therapy
Radiation therapy
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate renal function
Liver function
adequate liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
- Children's Hospital Los Angeles · Los Angeles, California
- Children's Hospital Colorado · Aurora, Colorado
- Children's National Hospital · Washington D.C., District of Columbia
- Ann & Robert H. Lurie Children's Hospital of Chicago · Chicago, Illinois
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06541847 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior HLX-1502, MEK inhibitor, tyrosine kinase inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify